Aprogen Biologics Inc.
Financials
Valuation Metrics
Aprogen Biologics Inc.'s Market Cap is ₩265B. At end of 2025 it was ₩84B. Ranked #2172 of 2,421 in KR market (top 90%), #759 of 781 on KOSPI (top 97%), #218 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 94%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 26.52B KRW | KR#2,172/2,421 Sec#218/231 |
| Revenue | 86.18B KRW | KR#1,502/2,421 Sec#94/231 |
| Net Income | -72.59B KRW | KR—/2,421 Sec—/231 |
| Total Assets | 548.41B KRW | KR#728/2,421 Sec#43/231 |
| Net Assets | 267.71B KRW | KR#782/2,421 Sec#51/231 |
| Employees | 427 | KR#575/2,421 Sec#46/231 |
| Value | ||
| P/B | 0.10x | KR#20/2,421 Sec#2/231 |
| P/S | 0.31x | KR#595/2,421 Sec#16/231 |
| FCF Yield | -180.44% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | -27.12% | KR#2,154/2,421 Sec#169/231 |
| ROA | -13.24% | KR#2,164/2,421 Sec#166/231 |
| Op. Margin | -67.00% | KR#2,268/2,421 Sec#164/231 |
| Revenue Growth | 26.13% | KR#432/2,421 Sec#43/231 |
| Financial Health | ||
| Debt Ratio | 104.85% | KR#1,606/2,421 Sec#184/231 |
| Total Debt | 334.33B KRW | KR#382/2,421 Sec#20/231 |
| FCF | -47.86B KRW | KR#2,077/2,421 Sec#205/231 |
| Cash | 22.43B KRW | KR#1,181/2,421 Sec#81/231 |
| Current Ratio | 0.57x | KR#2,102/2,421 Sec#200/231 |
| Dividend | ||
| Div. Yield | 0.00% | KR#1,393/2,421 Sec#87/231 |
| Performance | ||
| 1Y Return | 158.07% | KR#69/2,421 Sec#3/231 |
| 1M Return | -14.43% | KR#2,228/2,421 Sec#189/231 |
| From 52W High | -74.40% | KR#2,276/2,421 Sec#198/231 |
| 1Y MDD | -68.61% | KR#1,926/2,421 Sec#164/231 |
| Trading | ||
| Volume | 46,496 shares | KR#1,171/2,421 Sec#116/231 |
| Trading Value | 75.9M KRW | KR#1,675/2,421 Sec#171/231 |
| Foreign Own. | 0.00% | KR—/2,421 Sec—/231 |
| Per Share | ||
| EPS | -4,464 KRW | KR—/2,421 Sec—/231 |
| BPS | 16,463 KRW | KR#641/2,421 Sec#42/231 |
Company Info
Aprogen Biologics, founded in 1960, absorbed an affiliate with biopharmaceutical production facilities and technology in 2022, and also incorporated N2TEC, a semiconductor equipment component manufacturer and seller, as a subsidiary. The company's core businesses include pharmaceutical and bio divisions focused on medicine manufacturing and sales, as well as semiconductor equipment component production. Its Osong factory boasts the world's fifth-largest antibody production capacity and collaborates with Aprogen on the production and commercialization of biosimilar medicines. Aprogen Biologics is headquartered in Songpa-gu, Seoul.